Cyclerion Therapeutics (NASDAQ: CYCN)
$2.77
(-9.2%)
-$0.28
Price as of April 24, 2024, 9:38 a.m. ET
Cyclerion Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Cyclerion Therapeutics Company Info
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.
News & Analysis
Featured Article
Why Cyclerion Therapeutics Is Crashing Today
A second midstage failure is hurting the biotech's stock price today.
George Budwell | Oct 14, 2020
Featured Article
Here’s Why Cyclerion Therapeutics Stock Plummeted Today
A double clinical trial failure sends the biotech’s shares down.
Brian Orelli, PhD | Oct 30, 2019
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.